AllPeptides.eu - Advanced Peptide Research
    Single Peptides
    Growth_hormone

    HGH 191AA (100IU/33.3mg)

    Subcutaneous injectionDaily100IU/33.3mg

    Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16

    🇺🇸 FDA (Genotropin®)
    🇪🇺 EMA (Genotropin®)
    🇯🇵 PMDA
    🇨🇳 NMPA
    🇦🇺 TGA

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    FDA & EMA approved — for specific indications
    Educational information. Not medical advice or a recommendation for use.

    ⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer

    Research monograph

    See the full HGH 191aa encyclopedia page with mechanism, evidence tier, related variants and research context.

    Open monograph
    Free Access

    How It Works

    HGH 191AA binds to growth hormone receptors, triggering IGF-1 synthesis in the liver.

    Quick Start

    • Typical Dose: 2–4IU subcutaneously, daily
    • Frequency: Daily, morning or divided dose
    • Storage: 2–8°C after reconstitution
    Detailed Protocol Data

    Dosing Table — HGH 191AA 100IU/33.3mg

    Educational only
    Vial Size— affects syringe units
    BAC Water5 mL
    Concentration6.66 mg/mL

    Route: Subcutaneous injection | Frequency: Daily

    WeekDoseUnits (per injection)
    1–4
    2IU
    10 units (0.10mL)
    5–8
    3IU
    15 units (0.15mL)
    9+
    4IU
    20 units (0.20mL)

    Studies report administration fasted in the morning or split into 2 doses. Concentration: 20IU/mL.

    Related compounds

    Reconstitution Steps

    1. Clean vial stoppers with alcohol swab.
    2. Draw 5mL bacteriostatic water.
    3. Slowly inject into vial wall — do not shake.
    4. Gently swirl until fully dissolved (may take 10–15 minutes).
    5. Store refrigerated (2–8°C).

    Protocol Overview

    • HGH 191AA is biosynthetic growth hormone identical to endogenous GH.
    • It directly acts on GH receptors throughout the body.
    • Results are gradual over 4–12 weeks.

    Dosing Protocol

    • Introduction: 2IU/day for 4 weeks.
    • Increase to 3–4IU/day based on tolerance.
    • Anti-aging: 2–3IU. Athletic performance: 4–6IU.
    • Cycle: 3–6 months active.
    • Break between cycles: After cycle (3–6 months), a 8–12 week break is recommended.

    Washout & Cycle Restart

    When can I restart?

    After cycle (3–6 months), a 8–12 week break is recommended.

    Minimum wait period: 8 weeks

    Storage Instructions

    • Lyophilized: 2–8°C (ideal) or -20°C long-term.
    • Reconstituted: 2–8°C, use within 21 days.
    • Avoid vibration and light.

    Important Notes

    • Monitor IGF-1, fasting glucose, insulin.
    • Contraindicated in active neoplasia.
    • May cause fluid retention in the initial weeks.
    • Consult an endocrinologist before use.
    Clinical Analysis & Safety

    Potential Benefits & Side Effects

    Potential Benefits:

    • Increased muscle mass
    • Reduced body fat
    • Improved skin and hair quality
    • Enhanced injury recovery
    • Improved sleep quality
    • Anti-aging effects

    Potential Side Effects:

    • Fluid retention / edema
    • Joint pain
    • Carpal tunnel syndrome
    • Transient insulin resistance
    • Headache

    ⚠️ Serious Warnings & Long-Term Risks

    The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.

    🎗️ Cancer Markers
    🔴 High Risk

    Increased neoplasia risk (IGF-1 signaling)

    Chronic IGF-1 elevation is epidemiologically linked to increased risk of colorectal, prostate, and breast cancer. Contraindicated in active neoplasia.

    📄 Lancet Diabetes Endocrinol 2014; Endocr Rev 2009
    ❤️ Cardiovascular
    🔴 High Risk

    Cardiomegaly & arrhythmias

    Excessive GH/IGF-1 can cause myocardial hypertrophy, dysfunction, and increased cardiovascular risk (acromegaly analogue).

    📄 J Clin Endocrinol Metab 2004
    🧬 Endocrine
    🔴 High Risk

    Insulin resistance & Diabetes Mellitus

    GH is counter-insulin. Chronic use may worsen glycemic control or cause type 2 diabetes.

    📄 FDA Label — Genotropin®

    References

    1. Growth Hormone Therapy — Molitch ME, et al. J Clin Endocrinol Metab. 2011;96(6):1587-1609.
      View Source
    2. HGH Anti-Aging — Rudman D, et al. N Engl J Med. 1990;323(1):1-6.
      View Source

    Recommended Supplements

    Research Sources & Verified Data
    …
    Clinical Trials
    …
    PubMed Studies
    Approved
    FDA Status
    5
    Regulatory Approvals
    Verified across ClinicalTrials.gov, PubMed & FDA

    External Sources & Regulatory Status

    Regulatory Approvals

    🇺🇸
    FDA
    Approved

    Genotropin® / Norditropin® / others · GH deficiency / Turner / SGA (1985)

    🇪🇺
    EMA
    Approved

    Genotropin® / Omnitrope® · GH deficiency (1988)

    🇯🇵
    PMDA
    Approved

    GH deficiency

    🇨🇳
    NMPA
    Approved

    GH deficiency

    🇦🇺
    TGA
    Approved

    GH deficiency

    Approved worldwide (5+ countries)

    No official regulatory source available yet — research peptide.

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Summary:
    5 Approvals
    0 PubMed
    0 Clinical Studies

    Continue Your Research

    Explore tools and guides related to this protocol.

    Educational contentRegularly reviewed & maintainedEvidence-based review

    Important Disclaimer

    The content of this website is provided exclusively for informational and educational purposes within the context of research literature.

    Read the full Disclaimer →

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu